Peptide Lab HQ Research Guide
CJC-1295 (w/o DAC) + Ipamorelin
A research-focused blend profile covering CJC-1295 without DAC and Ipamorelin identity, GHRH and ghrelin receptor pathway research, growth hormone axis context, concentration reference, reconstitution reference, and safety considerations.
Blend Data
Compound Profile
| Blend Name | CJC-1295 (w/o DAC) + Ipamorelin |
|---|---|
| Blend Type | Dual-peptide endocrine research blend |
| Common Blend Composition | CJC-1295 w/o DAC 5 mg / Ipamorelin 5 mg |
| Total Vial Amount | 10 mg total blend content |
| Primary Components | CJC-1295 w/o DAC and Ipamorelin |
| CJC-1295 w/o DAC Component | Modified GRF (1-29), a synthetic GHRH analog used in growth hormone-releasing hormone receptor and pituitary signaling research. |
| Ipamorelin Component | Synthetic pentapeptide growth hormone secretagogue commonly studied in ghrelin receptor / GHS-R pathway research. |
| CJC-1295 w/o DAC Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| CJC-1295 w/o DAC Molecular Weight | Approximately 3367.9 g/mol |
| Ipamorelin Formula | C₃₈H₄₉N₉O₅ |
| Ipamorelin Molecular Weight | Approximately 711.9 g/mol |
| Research Category | GHRH receptor, ghrelin receptor, growth hormone axis, IGF-1 pathway, pituitary signaling, and endocrine-marker research |
| Appearance | White to off-white lyophilized powder |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
CJC-1295 (w/o DAC) + Ipamorelin is commonly discussed in controlled research models involving complementary growth hormone axis signaling, with CJC-1295 w/o DAC acting through GHRH receptor pathways and Ipamorelin acting through ghrelin / growth hormone secretagogue receptor pathways.
Growth Hormone Axis Research
This blend is commonly studied in research involving pituitary signaling, endogenous growth hormone release, IGF-1 pathway context, and endocrine-marker documentation.
GHRH Receptor Models
The CJC-1295 w/o DAC component is commonly treated as Modified GRF (1-29), a no-DAC GHRH analog used in receptor-signaling and pulse-dynamics research.
Ghrelin Receptor Research
The Ipamorelin component is studied as a selective growth hormone secretagogue / ghrelin receptor agonist in GH-release and pituitary-response models.
Combination Pathway Research
CJC-1295 w/o DAC and Ipamorelin are commonly discussed together because they interact with distinct receptor pathways involved in growth hormone signaling.
IGF-1 Pathway Context
Relevant to research involving downstream IGF-1 response, endocrine feedback, glucose-related markers, and GH-axis monitoring.
Endocrine Marker Research
Used in study contexts involving GH pulse timing, pituitary response, sleep-cycle observations, recovery markers, and body-composition endpoint tracking.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on peptide form, DAC status, component ratio, purity, concentration, timing, study model, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Quick Reference Summary
| Reference Vial | 10 mg total blend |
|---|---|
| Blend Ratio | Assumed 1:1 ratio: 5 mg CJC-1295 w/o DAC + 5 mg Ipamorelin |
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Total Blend Concentration | 5 mg/mL total blend |
| Approx. Component Concentration | 2.5 mg/mL CJC-1295 w/o DAC + 2.5 mg/mL Ipamorelin |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 5 mg/mL total blend, 1 unit equals 0.05 mg / 50 mcg total blend, or approximately 25 mcg CJC-1295 w/o DAC + 25 mcg Ipamorelin. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Because this is a blend, record the total blend amount and assumed component split unless the supplier label, COA, or batch record specifies a different ratio.
- Label with blend name, total vial amount, assumed ratio, total concentration, component concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Blend Identity Reference | CJC-1295 w/o DAC + Ipamorelin, 10 mg total blend | This reference treats the vial as a total blend amount. Unless otherwise specified, the calculation assumes a 1:1 ratio of 5 mg CJC-1295 w/o DAC and 5 mg Ipamorelin. |
| CJC-1295 w/o DAC Context | Modified GRF (1-29)-style / non-DAC GHRH analog context | CJC-1295 w/o DAC is commonly discussed in GHRH receptor, anterior pituitary, GH-marker, IGF-1 marker, and endocrine-axis research contexts. |
| Ipamorelin Context | Growth hormone secretagogue / ghrelin-receptor pathway context | Ipamorelin is commonly discussed in GHSR / ghrelin-receptor, GH-secretagogue, pituitary-response, and endocrine-marker research contexts. |
| Combination Research Context | GHRH analog + GHRP/GHSR pathway pairing | Public protocol-style references commonly pair modified GRF-style compounds with Ipamorelin in GH-axis research models. These references are not clinical dosing standards. |
| GH / IGF-1 Axis Research | Model-dependent endocrine-marker tracking | Research discussions commonly include GH-marker response, IGF-1 marker tracking, pituitary-axis response, somatotroph signaling, and endocrine feedback documentation. |
| DAC-Free Distinction | Non-DAC / no albumin-binding linker context | This reference is for the w/o DAC format of CJC-1295. It should not be treated the same as DAC-containing CJC-1295, which is commonly discussed separately as a longer-acting albumin-binding GHRH analog. |
| Public Protocol-Style Reference | Microgram-to-milligram total blend examples | Public protocol-style references commonly describe this blend in total microgram-to-milligram examples depending on preparation format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Total Blend Amount | Solution Volume | Total Blend Concentration | Approx. Component Concentration |
|---|---|---|---|
| 10 mg total blend | 2.0 mL | 5 mg/mL total blend | 2.5 mg/mL CJC-1295 w/o DAC + 2.5 mg/mL Ipamorelin |
Research Dosing Amount / Volume Reference
| Reference Amount | Approx. Component Split | Volume at 5 mg/mL Total Blend | U-100 Unit Reference | Approx. References per 10 mg Blend Vial |
|---|---|---|---|---|
| 50 mcg total blend | 25 mcg CJC-1295 w/o DAC + 25 mcg Ipamorelin | 0.01 mL | 1 unit | 200 |
| 100 mcg total blend | 50 mcg CJC-1295 w/o DAC + 50 mcg Ipamorelin | 0.02 mL | 2 units | 100 |
| 200 mcg total blend | 100 mcg CJC-1295 w/o DAC + 100 mcg Ipamorelin | 0.04 mL | 4 units | 50 |
| 250 mcg total blend | 125 mcg CJC-1295 w/o DAC + 125 mcg Ipamorelin | 0.05 mL | 5 units | 40 |
| 500 mcg total blend | 250 mcg CJC-1295 w/o DAC + 250 mcg Ipamorelin | 0.10 mL | 10 units | 20 |
| 1 mg / 1000 mcg total blend | 0.5 mg CJC-1295 w/o DAC + 0.5 mg Ipamorelin | 0.20 mL | 20 units | 10 |
| 2 mg / 2000 mcg total blend | 1 mg CJC-1295 w/o DAC + 1 mg Ipamorelin | 0.40 mL | 40 units | 5 |
| 5 mg / 5000 mcg total blend | 2.5 mg CJC-1295 w/o DAC + 2.5 mg Ipamorelin | 1.00 mL | 100 units | 2 |
| 10 mg / 10000 mcg total blend | 5 mg CJC-1295 w/o DAC + 5 mg Ipamorelin | 2.00 mL | 200 units | 1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Microgram Blend Reference | Calculation reference only | 50 mcg total blend reference amount | 1 unit / 0.01 mL |
| Standard Microgram Blend Reference | Public protocol-style reference, not a clinical dosing standard | 100 mcg total blend reference amount | 2 units / 0.02 mL |
| Mid Microgram Blend Reference | Public protocol-style reference, not a clinical dosing standard | 200 mcg total blend reference amount | 4 units / 0.04 mL |
| Upper Microgram Blend Reference | Public protocol-style reference, not a clinical dosing standard | 250 mcg total blend reference amount | 5 units / 0.05 mL |
| Low Milligram Conversion Example | Calculation reference only | 500 mcg total blend reference amount | 10 units / 0.10 mL |
| 1 mg Blend Preparation Reference | Preparation-level calculation reference | 1 mg total blend reference amount | 20 units / 0.20 mL |
| 2 mg Blend Preparation Reference | Preparation-level calculation reference | 2 mg total blend reference amount | 40 units / 0.40 mL |
| Half-Vial Blend Reference | Preparation-level calculation reference | 5 mg total blend reference amount | 100 units / 1.00 mL |
| Full-Vial Blend Reference | Preparation-level calculation reference | 10 mg total blend reference amount | 200 units / 2.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Receptor Observation Window | 24–72 hours | May be used for GHRH receptor signaling, GHSR pathway response, pituitary-axis marker context, intracellular signaling, or peptide-response documentation depending on the model. |
| Acute Endocrine Observation Window | Single session to several days | Used for short-term GH-marker comparison, pituitary-axis response, receptor-response timing, or early pathway tracking depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for early controlled observation involving GH-axis markers, IGF-1 marker tracking, endocrine-axis response, or blend-response comparison. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–8 weeks | Used when longer documentation is needed for endocrine-marker trends, GH / IGF-1 marker tracking, pituitary-axis response, or follow-up marker documentation. |
| Follow-Up / Washout | 1–4 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. This CJC-1295 w/o DAC + Ipamorelin reference treats the vial as a 10 mg total blend reconstituted with 2.0 mL bacteriostatic water, creating a 5 mg/mL total blend concentration. Unless otherwise specified, the blend is assumed to be 1:1, meaning approximately 5 mg CJC-1295 w/o DAC and 5 mg Ipamorelin per vial. CJC-1295 w/o DAC is commonly discussed in Modified GRF (1-29)-style, non-DAC GHRH analog, GHRH receptor, GH-axis, and IGF-1 marker research contexts. Ipamorelin is commonly discussed in GHSR / ghrelin-receptor, GH-secretagogue, pituitary-response, and endocrine-marker research contexts. Published study references, public protocol-style references, blend references, and wellness protocols are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
CJC-1295 w/o DAC + Ipamorelin is commonly discussed in research involving complementary GHRH receptor and ghrelin receptor pathway activation, pituitary signaling, growth hormone release, IGF-1 pathway context, and endocrine-marker tracking.
Blend Limitations
This is a dual-peptide blend rather than a single compound. Interpretation of research observations may vary based on component ratio, peptide form, DAC status, purity, model type, timing, and laboratory conditions.
Safety Considerations
Research discussion should account for GH-axis activity, IGF-1 response, glucose-related markers, water retention, injection-site response, appetite-related observations, and endocrine feedback monitoring.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.